KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Retained Earnings (2017 - 2025)

Moderna (MRNA) has disclosed Retained Earnings for 9 consecutive years, with $45.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Retained Earnings rose 550.0% to $45.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $45.0 million, a 550.0% increase, with the full-year FY2025 number at $45.0 million, up 550.0% from a year prior.
  • Retained Earnings was $45.0 million for Q4 2025 at Moderna, down from $8.0 billion in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of $16.9 billion in Q3 2022 to a low of -$1.0 billion in Q1 2021.
  • A 5-year average of $3.7 billion and a median of $500000.0 in 2024 define the central range for Retained Earnings.
  • Peak YoY movement for Retained Earnings: soared 106296.32% in 2021, then plummeted 1441.67% in 2022.
  • Moderna's Retained Earnings stood at -$24.0 million in 2021, then tumbled by 1441.67% to -$370.0 million in 2022, then skyrocketed by 66.76% to -$123.0 million in 2023, then surged by 91.87% to -$10.0 million in 2024, then surged by 550.0% to $45.0 million in 2025.
  • Per Business Quant, the three most recent readings for MRNA's Retained Earnings are $45.0 million (Q4 2025), $8.0 billion (Q3 2025), and $8.2 billion (Q2 2025).